CompletedPhase 2NCT06178055

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

Studying Central retinal artery occlusion

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kyoto Drug Discovery and Development Co., Ltd.
Principal Investigator: Kunihiro Musashi, MD., Ph.D.
Kyoto Drug Discovery ＆ Development Co., Ltd.
Intervention: KUS121 high dose(drug)
Enrollment: 17 enrolled
Eligibility: 20 years · All sexes
Timeline: 2024 – 2025

Study locations (11)

The Retina Partners, Encino, California, United States
Salehi Retina Institute, Inc, Huntington Beach, California, United States
Kaiser Permanente Oakland Med Ctr., Oakland, California, United States
Florida Retina Institute, Jacksonville, Florida, United States
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
Kresge Eye Institute/Wayne State University, Detroit, Michigan, United States
NYEE Infirmary of Mount Sinai, New York, New York, United States
UH Eye Institute, Cleveland, Ohio, United States
Austin Retina Associates, Austin, Texas, United States
Retina Consultants of Texas, San Antonio, Texas, United States
Retina Consultants of Texas, The Woodlands, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06178055 on ClinicalTrials.gov

Other trials for Central retinal artery occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal artery occlusion →

← Back to all trials